Metastatic colorectal cancer
Clinical trial efficacy: RAISE
RAISE trial: Efficacy overview
CYRAMZA + FOLFIRI demonstrated a statistically significant improvement in OS1
RAISE ITT OS: Median—Months (95% CI)1
Supportive outcome measure: Median PFS was 5.7 months with CYRAMZA + FOLFIRI1 (95% CI: 5.5, 6.2) (n=536) vs 4.5 months with placebo + FOLFIRI (95% CI: 4.2, 5.4) (n=536) (HR=0.79 [95% CI: 0.70, 0.90]); P<0.001
- The percentage of deaths at the time of analysis was 69% (372 patients) and 74% (397 patients) in the CYRAMZA + FOLFIRI and placebo + FOLFIRI arms, respectively1
- The percentage of events at the time of analysis was 89% (476 patients) and 92% (494 patients) in the CYRAMZA + FOLFIRI and placebo + FOLFIRI arms, respectively1
- 73 of 476 events in CYRAMZA-treated patients and 64 of 494 events in placebo-treated patients were deaths.
Consistent results in patients regardless of time to disease progression or KRAS status1-3
RAISE Subgroup OS: Median—Months (95% CI)
The RAISE trial was not adequately powered, nor error-controlled, for subgroup analyses. Treatment differences observed in these subgroups cannot be regarded as statistically significant. The analyses described here were prespecified and exploratory.
- Patients with time to disease progression on 1L ≥6 months (HR=0.86 [95% CI: 0.73, 1.01]): Median OS: 14.3 months with CYRAMZA + FOLFIRI (13.1, 15.5), n=411, vs 12.5 months with placebo + FOLFIRI (11.7, 13.6), n=407†
- Patients with wild-type KRAS (HR=0.82 [95% CI: 0.67, 1.00]): Median OS: 14.4 months with CYRAMZA + FOLFIRI (12.7, 16.1), n=267, vs 11.9 months with placebo + FOLFIRI (10.8, 13.3), n=275‡
RAISE Trial Design (N=1072)
The phase III RAISE trial evaluated the efficacy and safety of CYRAMZA plus FOLFIRI vs placebo plus FOLFIRI in patients with mCRC with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine. Major efficacy outcome measure was OS. Supportive efficacy outcome measure was PFS. All patients were required to have ECOG PS 0 or 1. Patients were stratified by geographic region, KRAS mutation status, and time to disease progression after the beginning of first-line treatment (<6 months vs ≥6 months). Patients were randomized 1:1 to receive either CYRAMZA 8 mg/kg (n=536) or placebo (n=536), in combination with FOLFIRI every 14 days.1